Abstract
The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
Original language | English |
---|---|
Article number | 47 |
Pages (from-to) | 1-14 |
Number of pages | 14 |
Journal | Clinical and Translational Allergy |
Volume | 6 |
DOIs | |
Publication status | Published - 30 Dec 2016 |
Keywords
- ARIA
- Rhinitis
- ICT
- EIP on AHA
- Mobile technology
- AIRWAYS ICPs
Access to Document
- 10.1186/s13601-016-0137-4Licence: CC BY
- Final Published Version
©The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Final published version, 1.53 MBLicence: CC BY
Fingerprint
Dive into the research topics of 'ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Clinical and Translational Allergy, Vol. 6, 47, 30.12.2016, p. 1-14.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - ARIA 2016
T2 - Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
AU - Bousquet, J
AU - Hellings, P W
AU - Agache, I
AU - Bedbrook, A
AU - Bachert, C
AU - Bergmann, K C
AU - Bewick, M
AU - Bindslev-Jensen, C
AU - Bosnic-Anticevitch, S
AU - Bucca, C
AU - Caimmi, D P
AU - Camargos, P A M
AU - Canonica, G W
AU - Casale, T
AU - Chavannes, N H
AU - Cruz, A A
AU - De Carlo, G
AU - Dahl, R
AU - Demoly, P
AU - Devillier, P
AU - Fonseca, J
AU - Fokkens, W J
AU - Guldemond, N A
AU - Haahtela, T
AU - Illario, M
AU - Just, J
AU - Keil, T
AU - Klimek, L
AU - Kuna, P
AU - Larenas-Linnemann, D
AU - Morais-Almeida, M
AU - Mullol, J
AU - Murray, R
AU - Naclerio, R
AU - O'Hehir, R E
AU - Papadopoulos, N G
AU - Pawankar, R
AU - Potter, P
AU - Ryan, D
AU - Samolinski, B
AU - Schunemann, H J
AU - Sheikh, A
AU - Simons, F E R
AU - Stellato, C
AU - Todo-Bom, A
AU - Tomazic, P V
AU - Valiulis, A
AU - Valovirta, E
AU - Ventura, M T
AU - Wickman, M
AU - Young, I
AU - Yorgancioglu, A
AU - Zuberbier, T
AU - Aberer, W
AU - Akdis, C A
AU - Akdis, M
AU - Annesi-Maesano, I
AU - Ankri, J
AU - Ansotegui, I J
AU - Anto, J M
AU - Arnavielhe, S
AU - Asarnoj, A
AU - Arshad, H
AU - Avolio, F
AU - Baiardini, I
AU - Barbara, C
AU - Barbagallo, M
AU - Bateman, E D
AU - Beghé, B
AU - Bel, E H
AU - Bennoor, K S
AU - Benson, M
AU - Białoszewski, A Z
AU - Bieber, T
AU - Bjermer, L
AU - Blain, H
AU - Blasi, F
AU - Boner, A L
AU - Bonini, M
AU - Bonini, S
AU - Bosse, I
AU - Bouchard, J
AU - Boulet, L P
AU - Bourret, R
AU - Bousquet, P J
AU - Braido, F
AU - Briggs, A H
AU - Brightling, C E
AU - Brozek, J
AU - Buhl, R
AU - Bunu, C
AU - Burte, E
AU - Bush, A
AU - Caballero-Fonseca, F
AU - Calderon, M A
AU - Camuzat, T
AU - Cardona, V
AU - Carreiro-Martins, P
AU - Carriazo, A M
AU - Carlsen, K H
AU - Carr, W
AU - Cepeda Sarabia, A M
AU - Cesari, M
AU - Chatzi, L
AU - Chiron, R
AU - Chivato, T
AU - Chkhartishvili, E
AU - Chuchalin, A G
AU - Chung, K F
AU - Ciprandi, G
AU - de Sousa, J Correia
AU - Cox, L
AU - Crooks, G
AU - Custovic, A
AU - Dahlen, S E
AU - Darsow, U
AU - Dedeu, T
AU - Deleanu, D
AU - Denburg, J A
AU - De Vries, G
AU - Didier, A
AU - Dinh-Xuan, A T
AU - Dokic, D
AU - Douagui, H
AU - Dray, G
AU - Dubakiene, R
AU - Durham, S R
AU - Du Toit, G
AU - Dykewicz, M S
AU - Eklund, P
AU - El-Gamal, Y
AU - Ellers, E
AU - Emuzyte, R
AU - Farrell, J
AU - Fink Wagner, A
AU - Fiocchi, A
AU - Fletcher, M
AU - Forastiere, F
AU - Gaga, M
AU - Gamkrelidze, A
AU - Gemicioğlu, B
AU - Gereda, J E
AU - van Wick, R Gerth
AU - González Diaz, S
AU - Grisle, I
AU - Grouse, L
AU - Gutter, Z
AU - Guzmán, M A
AU - Hellquist-Dahl, B
AU - Heinrich, J
AU - Horak, F
AU - Hourihane, J O' B
AU - Humbert, M
AU - Hyland, M
AU - Iaccarino, G
AU - Jares, E J
AU - Jeandel, C
AU - Johnston, S L
AU - Joos, G
AU - Jonquet, O
AU - Jung, K S
AU - Jutel, M
AU - Kaidashev, I
AU - Khaitov, M
AU - Kalayci, O
AU - Kalyoncu, A F
AU - Kardas, P
AU - Keith, P K
AU - Kerkhof, M
AU - Kerstjens, H A M
AU - Khaltaev, N
AU - Kogevinas, M
AU - Kolek, V
AU - Koppelman, G H
AU - Kowalski, M L
AU - Kuitunen, M
AU - Kull, I
AU - Kvedariene, V
AU - Lambrecht, B
AU - Lau, S
AU - Laune, D
AU - Le, L T T
AU - Lieberman, P
AU - Lipworth, B
AU - Li, J
AU - Lodrup Carlsen, K C
AU - Louis, R
AU - Lupinek, C
AU - MacNee, W
AU - Magar, Y
AU - Magnan, A
AU - Mahboub, B
AU - Maier, D
AU - Majer, I
AU - Malva, J
AU - Manning, P
AU - De Manuel Keenoy, E
AU - Marshall, G D
AU - Masjedi, M R
AU - Mathieu-Dupas, E
AU - Maurer, M
AU - Mavale-Manuel, S
AU - Melén, E
AU - Melo-Gomes, E
AU - Meltzer, E O
AU - Mercier, J
AU - Merk, H
AU - Miculinic, N
AU - Mihaltan, F
AU - Milenkovic, B
AU - Millot-Keurinck, J
AU - Mohammad, Y
AU - Momas, I
AU - Mösges, R
AU - Muraro, A
AU - Namazova-Baranova, L
AU - Nadif, R
AU - Neffen, H
AU - Nekam, K
AU - Nieto, A
AU - Niggemann, B
AU - Nogueira-Silva, L
AU - Nogues, M
AU - Nyembue, T D
AU - Ohta, K
AU - Okamoto, Y
AU - Okubo, K
AU - Olive-Elias, M
AU - Ouedraogo, S
AU - Paggiaro, P
AU - Pali-Schöll, I
AU - Palkonen, S
AU - Panzner, P
AU - Papi, A
AU - Park, H S
AU - Passalacqua, G
AU - Pedersen, S
AU - Pereira, A M
AU - Pfaar, O
AU - Picard, R
AU - Pigearias, B
AU - Pin, I
AU - Plavec, D
AU - Pohl, W
AU - Popov, T A
AU - Portejoie, F
AU - Postma, D
AU - Poulsen, L K
AU - Price, D
AU - Rabe, K F
AU - Raciborski, F
AU - Roberts, G
AU - Robalo-Cordeiro, C
AU - Rodenas, F
AU - Rodriguez-Mañas, L
AU - Rolland, C
AU - Roman Rodriguez, M
AU - Romano, A
AU - Rosado-Pinto, J
AU - Rosario, N
AU - Rottem, M
AU - Sanchez-Borges, M
AU - Sastre-Dominguez, J
AU - Scadding, G K
AU - Scichilone, N
AU - Schmid-Grendelmeier, P
AU - Serrano, E
AU - Shields, M
AU - Siroux, V
AU - Sisul, J C
AU - Skrindo, I
AU - Smit, H A
AU - Solé, D
AU - Sooronbaev, T
AU - Spranger, O
AU - Stelmach, R
AU - Sterk, P J
AU - Strandberg, T
AU - Sunyer, J
AU - Thijs, C
AU - Triggiani, M
AU - Valenta, R
AU - Valero, A
AU - van Eerd, M
AU - van Ganse, E
AU - van Hague, M
AU - Vandenplas, O
AU - Varona, L L
AU - Vellas, B
AU - Vezzani, G
AU - Vazankari, T
AU - Viegi, G
AU - Vontetsianos, T
AU - Wagenmann, M
AU - Walker, S
AU - Wang, D Y
AU - Wahn, U
AU - Werfel, T
AU - Whalley, B
AU - Williams, D M
AU - Williams, S
AU - Wilson, N
AU - Wright, J
AU - Yawn, B P
AU - Yiallouros, P K
AU - Yusuf, O M
AU - Zaidi, A
AU - Zar, H J
AU - Zernotti, M E
AU - Zhang, L
AU - Zhong, N
AU - Zidarn, M
N1 - European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, EU Structural and Development Fund Languedoc-Roussillon, ARIA.
PY - 2016/12/30
Y1 - 2016/12/30
N2 - The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
AB - The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
KW - ARIA
KW - Rhinitis
KW - ICT
KW - EIP on AHA
KW - Mobile technology
KW - AIRWAYS ICPs
U2 - 10.1186/s13601-016-0137-4
DO - 10.1186/s13601-016-0137-4
M3 - Article
C2 - 28050247
SN - 2045-7022
VL - 6
SP - 1
EP - 14
JO - Clinical and Translational Allergy
JF - Clinical and Translational Allergy
M1 - 47
ER -